Pneumococcal Vaccine Market Size, Share, Trends, Industry Analysis Report, By Vaccine Type (Pneumococcal Conjugate Vaccine, and Pneumococcal Polysaccharide Vaccine); By Product Type; By End User; By Region; Segment Forecast, 2024 - 2032

Pneumococcal Vaccine Market Size, Share, Trends, Industry Analysis Report, By Vaccine Type (Pneumococcal Conjugate Vaccine, and Pneumococcal Polysaccharide Vaccine); By Product Type; By End User; By Region; Segment Forecast, 2024 - 2032

The global pneumococcal vaccine market size is expected to reach USD 14.43 billion by 2032, according to a new study by Polaris Market Research. The report “Pneumococcal Vaccine Market Share, Size, Trends, Industry Analysis Report, By Vaccine Type (Pneumococcal Conjugate Vaccine, and Pneumococcal Polysaccharide Vaccine); By Product Type; By Distribution Channel; By Region; Segment Forecast, 2024-2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The pneumococcal vaccine market is experiencing significant growth driven by increased awareness about pneumococcal infections and the expansion of government-sponsored immunization programs. As public health campaigns highlight the dangers of pneumococcal disease, including pneumonia and meningitis, individuals and healthcare providers are more inclined to seek vaccination. Additionally, governments worldwide are implementing robust immunization initiatives aimed at enhancing community health and reducing healthcare costs associated with pneumococcal diseases. These programs often include subsidies and educational resources, making vaccines more accessible to underserved populations. As awareness continues to rise and vaccination efforts intensify, the demand for pneumococcal vaccines is expected to increase substantially, impacting the pneumococcal vaccine market growth positively.

The pneumococcal vaccine market is driven by government initiatives and health policies that promote widespread vaccination. These programs aim to enhance public health by reducing the incidence of pneumococcal diseases, such as pneumonia and meningitis. As governments implement comprehensive immunization strategies, including funding and awareness campaigns, accessibility to vaccines improves, leading to higher vaccination rates.

Increasing partnerships between biotech firms and market players aimed at developing more effective pneumococcal conjugate vaccines (PCVs) are fueling the pneumococcal vaccine market growth in forecast years. For Instance, in June 2023, SK Bioscience collaborated with Sanofi to create GBP410, a 21-valent PCV that demonstrated positive results in Phase 2 studies involving toddlers and infants. Similarly, in March 2024, Pfizer's PREVENAR 20, a 20-valent PCV, received approval from the European Commission to immunize infants, children, and adolescents across Europe and globally. These strategic alliances enhance research capabilities, expedite development timelines, and expand vaccine access, ultimately driving market growth during projected years.

Pneumococcal Vaccine Market Report Highlights

• The pneumococcal polysaccharide vaccine (PPV) segment accounted for the largest market share in 2023 primarily due to global acceptance and easy availability.
• The Pneumococcal conjugate vaccine (PCV) segment is expected to witness the highest growth over the study period, as PCV covers more range of the streptococcus pneumoniae.
• The Prevnar 13 segment accounted for the largest market share in 2023, as it caters to a wider range of age, and is more efficient in treating the disease.
• The Asia Pacific is projected to register the fastest growth over the study period, attributable to the increasing investment in pneumococcal vaccine development.
• The global players are GSK plc, Pfizer Inc, Merck, Serum Institute, CSL Ltd., and Sanofi.

Polaris Market Research has segmented the pneumococcal vaccine market report based on vaccine type, product type, distribution channel, and region:

By Vaccine Type Outlook (Revenue - USD Billion, 2019 - 2032)

• Pneumococcal conjugate vaccine (PCV)
• Pneumococcal polysaccharide vaccine (PPV)

By Product Type Outlook (Revenue - USD Billion, 2019 - 2032)

• Prevnar 13
• Synflorix
• Pneumovax23

By Distribution Channel Outlook (Revenue - USD Billion, 2019 - 2032)

• Distribution partner companies
• Non-governmental Organizations
• Government Authorities

By Regional Outlook (Revenue - USD Billion, 2019 - 2032)

• North America
• U.S.
• Canada
• Europe
• Germany
• UK
• France
• Italy
• Spain
• Russia
• Netherlands
• Asia Pacific
• China
• India
• Japan
• South Korea
• Indonesia
• Malaysia
• Latin America
• Argentina
• Brazil
• Mexico
• Middle East & Africa
• UAE
• Saudi Arabia
• Israel
• South Africa